Tag: cancer tumor profiling market

The global cancer profiling market is expected to yield significant gains across 2021, as preference for precision-based medicine and high quality oncology care acquires increasing traction. With global cancer burden slated to proliferate, patients and medical practitioners alike are scrambling to offer highly efficacious and long-lasting cancer diagnostics, prompting the entry of numerous service providers.

Key solution providers are effectively leveraging smart technology, nanomedicine, and automation to accelerate diagnostic processes. Reduction in testing timeframes to provide accurate results has helped patients seek timely treatment to mitigate their cancers. The report by Fact.MR provides a taxonomy elaborating on key market segments. It also outlines visionary insights on the dynamics of the market, including the drivers, restraints, opportunities, trends, and pricing analysis, along with key success factors. Market trends have been tracked in 20+ high-growth countries.

Request For Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=358

As per the research report compiled by Fact.MR, the global cancer profiling market is expected to witness strong growth, registering 17.7% CAGR during the forecast period 2017-2026. By the end of 2026, the global cancer profiling market is estimated to reach US$ 122,129.6 million revenue. Increasing incidences of new cases of cancer are resulting in the rising use of cancer profiling. As per National Cancer Institute, new cancer cases are likely to reach 22 million within next two years. Moreover, increasing adoption of precision medicine treatment is also driving the demand for cancer profiling. Below are the few insights on how the global cancer profiling market will perform in the coming years.

Forecast Highlights on Global Cancer Profiling Market

1- North America is expected to remain dominant in the global cancer profiling market during the forecast period 2017-2026. Changing lifestyle with increasing consumption of alcohol, smoking is leading to the increasing number of people suffering from cancer. Moreover, increasing investment in research and development activities are driving the demand for cancer profiling in the region.

2- Asia Pacific Excluding Japan (APEJ) and Europe are also witnessing significant growth in the cancer profiling. Increasing incidence of lung cancer and prostate cancer in central, eastern, and southern Europe is driving the demand for cancer profiling. Meanwhile, breast cancer is the most diagnosed cancer among women in China and India.

3- Next-generation sequencing is expected to be the highly-preferred technique in cancer profiling market. By the end of 2026, next-generation sequencing is estimated to reach 62,000 million revenue.

4- Pharmaceutical and biotech companies are expected to be the largest users of cancer profiling. Pharmaceutical and biotech companies are estimated to surpass US$ 52,400 million revenue by the end of 2026.

5- Diagnosis is expected to witness significant growth in the global cancer profiling market. By the end of 2026, diagnosis is estimated to surpass US$ 40,000 million in terms of revenue.

For customized report:  https://www.factmr.com/connectus/sample?flag=RC&rep_id=358

The report has also profiled leading players in the global market for cancer profiling, which will remain active through 2026. These include companies such as Roche Holdings, Caris Life Sciences, GenScript, Illumina, Inc. (U.S.), Proteome Sciences PLC, BioTheranostics, NeoGenomics Laboratories, RiboMed Biotechnologies Inc., Genomic Health Inc., Oxford Gene Technology Ltd., and Agendia.

Buy Now :  https://www.factmr.com/checkout/358/S

Country-wise Analysis

How Lucrative is the U.S. Cancer Profiling Market?

The United States is expected to garner significant share in the cancer profiling landscape. A study conducted by the American Cancer Society projects a substantial increase in the incidence of numerous cancers across the country in 2021. It estimates that, over 1.8 million people are expected to suffer from some or the other malignancy, with over 600 thousand deaths. Therefore, government initiatives have been undertaken to contain the spread of this debilitating disease. These include launching awareness campaigns and promoting highly advanced cancer profiling and detection research.

The National Cancer Institute has been playing a pivotal in advancing sophisticated cancer research studies and initiatives, including on cancer biology, cancer genomics, and cancer prevention. At present, the agency is working on determining the efficacy of patient derived xenograft (PDX) mice-based clinical trials. These mice largely retain the genetics of human tumors from which they were initially created. This is expected to reassure clinicians about the validity of novel cancer treatment and detection studies and approaches.

For more insights: https://www.biospace.com/article/autologous-fat-grafting-is-emerging-as-a-safer-substitute-to-breast-enlargement-procedures-fact-mr/

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

250 Pages Cancer Profiling Market Survey by Fact MR, A Leading Business and Competitive Intelligence Provider

Fact MR analysis of cancer profiling market provides compelling insights into the factors propelling sales prospects in key segments such as Product Type, Indication, and Test Type ,End User. It provides an executive-level blueprint of key market players’ strategies and analyses their impact on overall growth projections.

According to the study, cancer profiling market revenues continue to remain consolidated in North America. Of the estimated new cases, breast cancer accounts for over 15% and colorectal cancer for about 8% new cases. As breast and colorectal cancers are few of the leading causes of death in North America, collectively they register nearly 70% of total regional cancer profiling revenues.

Focus on improving overall patient care will remain a chief growth driver. Besides this, cancer profiling market will continue gaining from increasing willingness among patients and families to spend on advanced healthcare.

To offer an in-depth overview, the report provides sales projections for over 20 countries. It also identifies segments exhibiting maximum growth potential on the basis of Product Type, Indication, and Test Type.

Request a Report Sample to Gain Comprehensive Market Insights at
https://www.factmr.com/connectus/sample?flag=S&rep_id=358

Digital Transformation in Healthcare Presenting Opportunities for Cancer Profiling Market Growth

Healthcare organizations around the world are deploying digital tools to accommodating changing consumer preferences. They are pressing on solving the long-standing challenge pertaining to care model innovation.

Considering this, the focus on making healthcare affordable and more transparent will increase. Adoption of care model innovation in healthcare will have a profound impact on the cancer profiling market.

Key Cancer Profiling Survey Highlights and Projections

Driven by higher investment in innovation, the U.S. will emerge as the dominant Cancer Profiling market in North America, accounting for 4.7% of overall sales registered in 2028.

With the presence of some of the world’s leading healthcare companies, coupled with high spending on hospital services, the U.K. and Germany will emerge as highly lucrative pockets in Europe.

Investment towards healthcare sector expansion and focus on medical tourism will make China, Japan, and South Korea key markets within East Asia.

Speak to Research Analyst

https://www.factmr.com/connectus/sample?flag=AE&rep_id=358

Report Benefits & Key Questions Answered

Cancer Profiling Category and segment level analysis: Fact MR provides a detailed analysis of the factors influencing sales growth across key segments. It highlights key growth drivers and provides useful information for identifying sales prospects at the regional and local level.

Cancer Profiling Historical volume analysis: The report provides a comparison of Cancer Profiling’s historical sales and projected sales performance for 2021-2031.

Cancer Profiling Manufacturing trend analysis: The report offers a detailed analysis of manufacturing trends in the Cancer Profiling market. It carefully gauges the impact of changing healthcare needs of key demographics globally

Cancer Profiling Consumption by demographics: The report investigates consumer behavior affecting Cancer Profiling demand outlook for the assessment period. Effect of their keenness for digital trends on Cancer Profiling market is carefully analyzed

Post COVID consumer spending on Cancer Profiling: Healthcare industry has been largely influenced by COVID-19 pandemic. The Fact MR Market survey analyzed consumer spending post COVID-19. It assesses how current trends that will influence expenditure on healthcare services, thus affecting Cancer Profiling market growth.

Competitive Landscape Analysis

The study offers insights into key trends affecting healthcare industry, subsequently influencing demand supply forces in the Cancer Profiling market.

• F. Hoffmann La Roche Ltd
• Illumina Inc
• QIAGEN
• Thermo Fisher Scientific Inc
• Abbott
• Nanostring Technologies Inc
• Siemens AG
• HTG Molecular Diagnostics, Inc
• Perkin Elmer Inc
• Agilent Technologies Inc
• Negenomics Laboratory Inc

To offer an in-depth analysis of prevailing competition, the report offers a detailed market share analysis. In this chapter market players are segregated in terms of Tier 1, Tier 2, and Tier 3 companies. Strategies adopted by players across these categories and impact of the same on the overall market are studied at length.

Full Access of this Report Is Available at https://www.factmr.com/checkout/358

Cancer Profiling Demand Analysis by Category

Product Type

Immunohistochemistry (IHC) Analyzers
Fluorescence In situ Hybridization (FISH) Instruments
PCR instruments
DNA Sequencer
Fragment Analyzer
Consumables
Reagents & Kits
Other Ancillary (probes, holders etc.)

By Indication

Breast Cancer
Colorectal Cancer
Ovarian Cancer
Melanoma
Kidney Cancer
Lung Cancer (including NSCLC)
Rare Cancers

By End User

Hospitals
Diagnostic Centres
Cancer Research Institutes

Region

North America
Europe
East Asia
South Asia
Oceania
Middle East and Africa

For More Insights https://www.biospace.com/article/linear-motion-systems-sales-surged-by-increment-in-industrial-production-across-the-globe-says-fact-mr/

Cancer Profiling Market – Additional Questions Answered

In addition to the aforementioned insights, the cancer profiling market report delivers intelligent insights based on a thorough assessment of all the market facets. These insights can answer to some of the bemusing questions of the business professional interested in the cancer profiling market.

• Which product type in the cancer profiling market will register significant demand by the end of the assessment period?
• Which region presents considerable utilization of cancer profiling tools?
• Among different test types, which test type will be highly sought after in the cancer profiling market during the forecast period?
• Which end-user will register leading utilization of cancer profiling tests during the forecast period?

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in the US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com

Cancer profiling has emerged as one of the leading approaches used in identification, prognosis, research analysis and treatment of various cancers. Various approaches such as proteomics, genomics, and metabolomics are being used in cancer profiling. Also, precision medicine treatment is being adopted on a large scale in order to analyze individual genetic profiles and offer personalized treatments. Moreover, cancer is the focus of precision medicine. Moreover, around 631 cancer therapies are in the global oncology research and development pipeline.

Next-generation sequencing in the cancer profiling is helping in identifying multiple tumor mutations. Many cancer centers have already adopted next-gen sequencing-based genetic profiling using target gene capturing. Oncologists across the world are using cancer profiling method along with the rise in adoption of cancer biomarkers for tumor profiling. Moreover, factors including point-of-care diagnostic test, and rising demand for personalized medicine is offering opportunities for leading companies in the cancer profiling market.

Request For Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=358

As per the research report compiled by Fact.MR, the global cancer profiling market is expected to witness strong growth, registering 17.7% CAGR during the forecast period 2017-2026. By the end of 2026, the global cancer profiling market is estimated to reach US$ 122,129.6 million revenue. Increasing incidences of new cases of cancer are resulting in the rising use of cancer profiling. As per National Cancer Institute, new cancer cases are likely to reach 22 million within next two years. Moreover, increasing adoption of precision medicine treatment is also driving the demand for cancer profiling. Below are the few insights on how the global cancer profiling market will perform in the coming years.

Forecast Highlights on Global Cancer Profiling Market

1- North America is expected to remain dominant in the global cancer profiling market during the forecast period 2017-2026. Changing lifestyle with increasing consumption of alcohol, smoking is leading to the increasing number of people suffering from cancer. Moreover, increasing investment in research and development activities are driving the demand for cancer profiling in the region.

2- Asia Pacific Excluding Japan (APEJ) and Europe are also witnessing significant growth in the cancer profiling. Increasing incidence of lung cancer and prostate cancer in central, eastern, and southern Europe is driving the demand for cancer profiling. Meanwhile, breast cancer is the most diagnosed cancer among women in China and India.

Request Methodology & Get a Glimpse of Our Expertise
https://www.factmr.com/connectus/sample?flag=RM&rep_id=358

3- Next-generation sequencing is expected to be the highly-preferred technique in cancer profiling market. By the end of 2026, next-generation sequencing is estimated to reach 62,000 million revenue.

4- Pharmaceutical and biotech companies are expected to be the largest users of cancer profiling. Pharmaceutical and biotech companies are estimated to surpass US$ 52,400 million revenue by the end of 2026.

5- Diagnosis is expected to witness significant growth in the global cancer profiling market. By the end of 2026, diagnosis is estimated to surpass US$ 40,000 million in terms of revenue.

The report has also profiled leading players in the global market for cancer profiling, which will remain active through 2026. These include companies such as Roche Holdings, Caris Life Sciences, GenScript, Illumina, Inc. (U.S.), Proteome Sciences PLC, BioTheranostics, NeoGenomics Laboratories, RiboMed Biotechnologies Inc., Genomic Health Inc., Oxford Gene Technology Ltd., and Agendia.

Get More Insights- https://www.globenewswire.com/fr/news-release/2018/04/24/1486281/0/en/Key-Takeaways-from-Fact-MR-s-Report-on-Cancer-Profiling-Market-for-Forecast-Period-2018-2026.html

Explore FACT.MR’s Comprehensive Coverage of Healthcare Landscape

Phototherapy Devices Market– Get the latest insights on the phototherapy devices market through FACT.MR’s report covering analysis for projection period (2017-2022).

Radiotherapy Devices Market– FACT.MR’s study on the global radiotherapy devices market covers trends, tech innovations, players, and strategies for 2017-2022.

Dermatology Devices Market– Obtain analysis on the dermatology devices market through FACT.MR’s latest report covering competitive analysis, key regions, along with segmental analysis for 2017-2022.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com
Research Insight: https://www.factmr.com/report/358/cancer-profiling-market
Press Release: https://www.factmr.com/media-release/802/global-cancer-profiling-market